Cancer Research Archives
Apr. 20, 2017—A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.
Nov. 13, 2015—Vanderbilt University may nominate one candidate for the Mary Kay Foundation Translational Cancer Research Grant program for 2016.
Feb. 12, 2015—The V Scholar Award supports young tenure-track faculty to begin their cancer research career.
Feb. 12, 2015—Vanderbilt may nominate one candidate for the V Foundation 2015 Translational Grant.
Jan. 8, 2015—Melanoma is the most lethal form of skin cancer, with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and the cancer advances.